Meanwhile, in pancreatic cancer, the application of PI3K/AKT pathway inhibitors enhances cell apoptosis, which in turn leads to a significant increase in radiosensitivity of ARID1A-deficient pancreatic cancer cells (76), and the sensitivity of ARID1A-depleted cancer cells to treatment with inhibitors of the PI3K/AKT pathway is increased by the loss of ARID1A expression (106). Here, AKT1 is linked to familial pancreatic carcinoma.